• Skip to main content

Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

  • How To Publish
  • How to Write Plain Language Summaries
  • Frequently Asked Questions
  • Publications
    • Animated Videos
    • Bladder, Kidney and Genitals
    • Brain and Nerves
    • Cancer
    • Diabetes and Metabolic Hormones
    • Eyes and Vision
    • Heart and Circulation
    • Infections
    • Inflammatory and Immune-related disorders
    • Mental Health
    • Muscle and Bone
    • Rare Diseases
    • Skin
    • Vaccines
  • Advisory Panel
  • Supporters
  • Blog
  • About Us
  • Contact Us

Sep 20 2022

Plain language summary of the VOLTAIRE-RA study in patients with moderate-to-severe rheumatoid arthritis

The latest plain language summary of publication from Immunotherapy presents results from the VOLTAIRE-RA study looking at how effective and safe the biosimilar drug BI 695501 is in treating people with rheumatoid arthritis.

Read the summary here.

The original article on which this summary is based is called ‘Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study’ and was originally published in the journal Annals of the Rhematic Diseases. The original article can be read here.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

Written by Joanne Walker · Categorized: Inflammatory and Immune-related disorders, Muscle and Bone, Novel Technologies and Treatments · Tagged: adalimumab, BI 695501, biosimilar, humira, lay summary, plain-language summary

Copyright © 2023 · Plain Language Summaries · Terms and Conditions · Privacy Policy ·